Complement therapeutics in inflammatory diseases: promising drug candidates for C3-targeted intervention

Area of Science:

• Immunology
• Pharmacology
• Oral Medicine

Background:

• Complement system dysregulation is implicated in numerous immune-mediated and inflammatory disorders.
• Approved complement inhibitors have shown significant impact in treating specific complement-mediated diseases.
• The central complement component C3 is a key target for therapeutic intervention due to its role in modulating immune responses.

Purpose of the Study:

• To review emerging therapeutic concepts and developments in C3-targeted drug candidates.
• To highlight the potential of C3 inhibition as a novel immunotherapeutic strategy.
• To use compstatin inhibitors and periodontitis as examples for oral and systemic inflammatory diseases.

Main Methods:

• Review of preclinical disease models demonstrating C3 interception benefits.
• Analysis of compstatin family C3 inhibitors.
• Exploration of C3's role in modulating innate and adaptive immunity.

Main Results:

• C3 inhibition shows promise as a therapeutic approach for various inflammatory disorders.
• Compstatins represent a clinically developed class of C3 inhibitors.
• C3 interception may offer advantages over existing therapies and address diseases not typically considered complement-driven, like periodontal disease.

Conclusions:

• C3-targeted therapies represent a promising frontier in immunotherapeutics.
• Compstatin-based C3 inhibitors are advancing as potential treatments for oral and systemic inflammatory conditions.
• Targeting C3 offers novel therapeutic avenues for a range of diseases, including those not traditionally linked to complement pathways.